Baidu
map

AACR 2021:抗CD47抗体AO-176治疗实体瘤和多发性骨髓瘤,临床前试验取得积极结果

2021-03-11 Allan MedSci原创

生物技术公司Arch Oncology今天宣布,在美国癌症研究协会(AACR)年会上介绍了AO-176的最新临床前数据。

生物技术公司Arch Oncology今天宣布,在美国癌症研究协会(AACR)年会上介绍了AO-176的最新临床前数据。AO-176是一种抗CD47抗体,可通过阻断“don't eat me”信号并直接杀死肿瘤细胞而发挥作用,并优先与肿瘤细胞结合。目前,AO-176正在I/II期临床试验中进行评估,以单一疗法或与标准疗法相结合的方式治疗部分实体瘤和多发性骨髓瘤。

AO-176是一种人源化的抗CD47 IgG2抗体。AO-176通过阻止“don't eat me”信号(抗CD47抗体的标准机制)起作用。除阻断该信号外,AO-176还具有其他机制,包括直接杀死肿瘤细胞和诱导DAMP(损伤相关分子模式),从而导致免疫原性细胞死亡。重要的是,AO-176优先与肿瘤细胞结合,而不与正常细胞结合,并且在酸性微环境(低pH)中更有效地与肿瘤结合。

Arch Oncology首席科学官Daniel Pereira博士说:“我们将在今年的AACR上展示两个新的非临床数据集,以证明AO-176在淋巴瘤和儿科T-ALL中具有强大的治疗潜力。在淋巴瘤中,AO-176在淋巴瘤异种移植物中表现出很强的活性。在酸性pH下,AO-176能够与淋巴瘤细胞的结合。AO-176或与利妥昔单抗联合使用。最后,还将介绍AO-176独特的诱导膜联蛋白V和DAMPs的独特能力,这些蛋白最终可能有助于诱导淋巴瘤细胞的免疫原性细胞死亡”。

 

原始出处:

https://www.firstwordpharma.com/node/1808442?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864292, encodeId=f299186429242, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 18 08:16:20 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890229, encodeId=2d661890229ad, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Jun 27 11:16:20 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951904, encodeId=acf0951904d7, content=<a href='/topic/show?id=d86643418d' target=_blank style='color:#2F92EE;'>#CD47抗体#</a>作为<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与<a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>,针对肿瘤蛋白靶向降解<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4341, encryptionId=d86643418d, topicName=CD47抗体), TopicDto(id=48167, encryptionId=e2a54816ecc, topicName=巨噬细胞), TopicDto(id=12852, encryptionId=8dcd12852f1, topicName=NK细胞), TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗), TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:54:31 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400494, encodeId=eb331400494b6, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947347, encodeId=d88b94e34790, content=学习了,受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Thu Mar 11 10:03:47 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864292, encodeId=f299186429242, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 18 08:16:20 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890229, encodeId=2d661890229ad, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Jun 27 11:16:20 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951904, encodeId=acf0951904d7, content=<a href='/topic/show?id=d86643418d' target=_blank style='color:#2F92EE;'>#CD47抗体#</a>作为<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与<a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>,针对肿瘤蛋白靶向降解<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4341, encryptionId=d86643418d, topicName=CD47抗体), TopicDto(id=48167, encryptionId=e2a54816ecc, topicName=巨噬细胞), TopicDto(id=12852, encryptionId=8dcd12852f1, topicName=NK细胞), TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗), TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:54:31 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400494, encodeId=eb331400494b6, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947347, encodeId=d88b94e34790, content=学习了,受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Thu Mar 11 10:03:47 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-06-27 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864292, encodeId=f299186429242, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 18 08:16:20 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890229, encodeId=2d661890229ad, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Jun 27 11:16:20 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951904, encodeId=acf0951904d7, content=<a href='/topic/show?id=d86643418d' target=_blank style='color:#2F92EE;'>#CD47抗体#</a>作为<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与<a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>,针对肿瘤蛋白靶向降解<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4341, encryptionId=d86643418d, topicName=CD47抗体), TopicDto(id=48167, encryptionId=e2a54816ecc, topicName=巨噬细胞), TopicDto(id=12852, encryptionId=8dcd12852f1, topicName=NK细胞), TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗), TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:54:31 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400494, encodeId=eb331400494b6, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947347, encodeId=d88b94e34790, content=学习了,受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Thu Mar 11 10:03:47 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-03-28 病毒猎手

    #CD47抗体#作为#巨噬细胞#信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与#NK细胞#活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现#mRNA疫苗#,针对肿瘤蛋白靶向降解#PROTAC#,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1864292, encodeId=f299186429242, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 18 08:16:20 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890229, encodeId=2d661890229ad, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Jun 27 11:16:20 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951904, encodeId=acf0951904d7, content=<a href='/topic/show?id=d86643418d' target=_blank style='color:#2F92EE;'>#CD47抗体#</a>作为<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与<a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>,针对肿瘤蛋白靶向降解<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4341, encryptionId=d86643418d, topicName=CD47抗体), TopicDto(id=48167, encryptionId=e2a54816ecc, topicName=巨噬细胞), TopicDto(id=12852, encryptionId=8dcd12852f1, topicName=NK细胞), TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗), TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:54:31 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400494, encodeId=eb331400494b6, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947347, encodeId=d88b94e34790, content=学习了,受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Thu Mar 11 10:03:47 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-03-13 10518094zz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864292, encodeId=f299186429242, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 18 08:16:20 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890229, encodeId=2d661890229ad, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Jun 27 11:16:20 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951904, encodeId=acf0951904d7, content=<a href='/topic/show?id=d86643418d' target=_blank style='color:#2F92EE;'>#CD47抗体#</a>作为<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与<a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>,针对肿瘤蛋白靶向降解<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4341, encryptionId=d86643418d, topicName=CD47抗体), TopicDto(id=48167, encryptionId=e2a54816ecc, topicName=巨噬细胞), TopicDto(id=12852, encryptionId=8dcd12852f1, topicName=NK细胞), TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗), TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:54:31 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400494, encodeId=eb331400494b6, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947347, encodeId=d88b94e34790, content=学习了,受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Thu Mar 11 10:03:47 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-03-13 Luyuxie_14
  6. [GetPortalCommentsPageByObjectIdResponse(id=1864292, encodeId=f299186429242, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue May 18 08:16:20 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890229, encodeId=2d661890229ad, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Jun 27 11:16:20 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951904, encodeId=acf0951904d7, content=<a href='/topic/show?id=d86643418d' target=_blank style='color:#2F92EE;'>#CD47抗体#</a>作为<a href='/topic/show?id=e2a54816ecc' target=_blank style='color:#2F92EE;'>#巨噬细胞#</a>信号,在巨噬细胞抗癌中发挥主要作用,与PD-1类药物联合使用,充分将巨噬细胞+T细胞双重激活,应该具有一定的协同作用。未来与<a href='/topic/show?id=8dcd12852f1' target=_blank style='color:#2F92EE;'>#NK细胞#</a>活化分子再结合,可能真正能解决大部分实体瘤的问题,未来远景可能也就10年时间,应该又是一个划时代进步。到2030年以后,会针对肿瘤的蛋白和基因,出现<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>,针对肿瘤蛋白靶向降解<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>,以及更针对性的肿瘤基因治疗出现,肿瘤届时真正成为慢病了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4341, encryptionId=d86643418d, topicName=CD47抗体), TopicDto(id=48167, encryptionId=e2a54816ecc, topicName=巨噬细胞), TopicDto(id=12852, encryptionId=8dcd12852f1, topicName=NK细胞), TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗), TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:54:31 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400494, encodeId=eb331400494b6, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552030, encodeId=69da1552030b7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Sat Mar 13 00:16:20 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947347, encodeId=d88b94e34790, content=学习了,受教, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Thu Mar 11 10:03:47 CST 2021, time=2021-03-11, status=1, ipAttribution=)]
    2021-03-11 356947897

    学习了,受教

    0

相关资讯

Eur Radiol: 骨髓ADC值是否可指导临床预测多发性骨髓瘤患者的预后?

多发性骨髓瘤患者的疾病进展和死亡风险分层对于早期识别需要不同治疗策略的高风险患者十分重要

NEJM:Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功

超过7成的难治性和复发性骨髓瘤患者在接受ide-cel治疗后有应答,其中近3成患者实现微小残留疾病阴性,几乎所有患者出现3级或4级不良事件,最常见的是血液学毒性和细胞因子释放综合征

CHMP建议批准Sarclisa(isatuximab)与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

与单独使用Kd相比,Sarclisa联合Kd将患者的疾病进展或死亡风险降低了47%。

Nat Med:多发性骨髓瘤患者在BCMA靶向CAR-T治疗后或引起BCMA纯合缺失

B细胞成熟抗原(BCMA)作为多种免疫疗法的靶点,也是多发性骨髓瘤(MM)中与肿瘤负荷相关的生物标志物。

Eur Radiol:如何评价多发性骨髓瘤的结构与异质性?

将纹理分析技术应用在多发性骨髓瘤CT图像上,可以获得更多的信息,从而更准确地表征肿瘤的结构和异质性。

FDA批准PEPAXTO(美法仑氟苯甲酰胺)用于治疗复发难治多发性骨髓瘤

PEPAXTO是一款抗癌肽-药物偶联物(PDC),其靶向氨基肽酶并将烷基化剂迅速释放到肿瘤细胞中。

拓展阅读

FDA发布《ctDNA用于治疗性实体瘤药物开发的行业指南》,为以ctDNA为生物标志物的临床试验提供指导

FDA 发布指南,为早期实体瘤药物研发中使用 ctDNA 作生物标志物提供指导,涵盖其应用发展、检测要点等多方面内容,以规范相关药物开发流程。

CAR-T治疗实体瘤获得实质性突破!IL-15加持、靶向GPC3;发表于Nature

本研究旨在评估IL-15共表达对GPC3表达的CAR-T细胞(以下简称GPC3 CAR-T细胞)的影响,对GPC3阳性实体瘤患者的治疗效果。

J HEMATOL ONCOL | 艾帕洛利单抗在 MSI-H/dMMR难治性或转移性实体瘤患者中的疗效和安全性:一项关键性、单臂、多中心、II 期试验

该研究旨在评估艾帕洛利单抗在MSI-H/dMMR不可切除或转移性实体瘤患者中的疗效和安全性,结果显示艾帕洛利单抗展现出令人鼓舞的抗肿瘤活性,为MSI-H/dMMR实体瘤患者提供了一种新的治疗选择。

“绘”解读真报告丨实体瘤全外显子组基因检测“小题大做”?真实案例多角度告诉你“并非如此”!

实体瘤全外显子组基因检测(WES)并非小题大做。通过案例阐述其能检出关键融合变异、提供肿瘤发生发展基因信息及对未知突变给出解读,为肿瘤患者带来全面且有价值的检测指导。实体瘤全外显子组基因检测(WES)

精准肿瘤学的斯芬达克斯之谜

探讨精准肿瘤学未来十年需解决的六个难题,包括治疗时机、突变致病性、组织嗜性、肿瘤克隆、患者因素、免疫治疗时机,以优化实体瘤治疗。

JCO:重磅ADC对13种癌症有效,疾病控制率达90.3%!

研究结果显示,在通过cfDNA检测出的晚期HER2扩增实体瘤患者中,给予T-DXd治疗可带来持久缓解,客观缓解率(ORR)达56.5%,疾病控制率(DCR)达90.3%,且总体安全性良好。

Baidu
map
Baidu
map
Baidu
map